Esperion Therapeutics (ESPR) Competitors $2.17 +0.04 (+1.88%) Closing price 04:00 PM EasternExtended Trading$2.17 0.00 (0.00%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. BHVN, SDGR, EWTX, EVO, ABCL, JANX, ARDX, WVE, VERA, and ETNBShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Biohaven (BHVN), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), Evotec (EVO), AbCellera Biologics (ABCL), Janux Therapeutics (JANX), Ardelyx (ARDX), WAVE Life Sciences (WVE), Vera Therapeutics (VERA), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Its Competitors Biohaven Schrodinger Edgewise Therapeutics Evotec AbCellera Biologics Janux Therapeutics Ardelyx WAVE Life Sciences Vera Therapeutics 89BIO Esperion Therapeutics (NASDAQ:ESPR) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Which has preferable earnings & valuation, ESPR or BHVN? Esperion Therapeutics has higher revenue and earnings than Biohaven. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$332.31M1.32-$51.74M-$0.49-4.43BiohavenN/AN/A-$846.42M-$7.66-2.04 Does the media favor ESPR or BHVN? In the previous week, Biohaven had 49 more articles in the media than Esperion Therapeutics. MarketBeat recorded 52 mentions for Biohaven and 3 mentions for Esperion Therapeutics. Biohaven's average media sentiment score of 0.17 beat Esperion Therapeutics' score of 0.00 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 6 Very Positive mention(s) 8 Positive mention(s) 26 Neutral mention(s) 7 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in ESPR or BHVN? 47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 1.7% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 16.0% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, ESPR or BHVN? Esperion Therapeutics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Is ESPR or BHVN more profitable? Biohaven has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -35.84%. Esperion Therapeutics' return on equity of -0.91% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-35.84% -0.91% -28.41% Biohaven N/A -270.65%-143.70% Do analysts prefer ESPR or BHVN? Esperion Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 222.58%. Biohaven has a consensus target price of $54.23, indicating a potential upside of 247.28%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than Esperion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Biohaven 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07 SummaryBiohaven beats Esperion Therapeutics on 11 of the 16 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$429.46M$2.57B$5.76B$9.58BDividend YieldN/A1.67%4.41%4.09%P/E Ratio-4.4322.6131.1026.05Price / Sales1.32742.38459.33116.07Price / Cash88.65180.4637.7358.48Price / Book-1.015.939.536.61Net Income-$51.74M$31.83M$3.26B$265.56M7 Day Performance5.85%1.80%2.11%1.98%1 Month Performance77.87%4.36%5.12%1.33%1 Year Performance26.90%11.44%31.25%21.15% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics3.5843 of 5 stars$2.17+1.9%$7.00+222.6%+21.0%$429.46M$332.31M-4.43200BHVNBiohaven3.8455 of 5 stars$13.42-8.9%$58.46+335.5%-64.6%$1.37BN/A-1.43239Trending NewsAnalyst ForecastOptions VolumeGap UpSDGRSchrodinger3.1292 of 5 stars$18.63-3.0%$32.75+75.8%-2.5%$1.37B$207.54M-7.51790EWTXEdgewise Therapeutics2.6234 of 5 stars$12.99+2.4%$40.64+212.8%-30.2%$1.37BN/A-8.3860Analyst ForecastEVOEvotec1.6016 of 5 stars$3.81-3.1%$5.90+54.9%+14.2%$1.35B$862.40M0.004,827Gap DownABCLAbCellera Biologics2.3265 of 5 stars$4.50+5.9%$8.00+77.8%+62.9%$1.34B$28.83M-8.18500Gap UpJANXJanux Therapeutics2.1337 of 5 stars$22.67-0.7%$91.89+305.3%-46.5%$1.34B$9.34M-12.5930ARDXArdelyx4.3371 of 5 stars$5.40+3.6%$11.50+113.0%-4.1%$1.30B$333.61M-23.4890Positive NewsWVEWAVE Life Sciences4.7967 of 5 stars$8.10+0.1%$20.27+150.2%+66.8%$1.29B$108.30M-9.00240Positive NewsVERAVera Therapeutics3.7665 of 5 stars$20.17+1.9%$63.00+212.3%-43.4%$1.29BN/A-5.6340Positive NewsETNB89BIO2.0524 of 5 stars$8.77-4.3%$26.29+199.7%+3.3%$1.28BN/A-2.4340 Related Companies and Tools Related Companies Biohaven Competitors Schrodinger Competitors Edgewise Therapeutics Competitors Evotec Competitors AbCellera Biologics Competitors Janux Therapeutics Competitors Ardelyx Competitors WAVE Life Sciences Competitors Vera Therapeutics Competitors 89BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access